Slingshot members are tracking this event:
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Slingshot Insights Explained
Nov 08, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3, Ixekizumab, Psoriatic Arthritis, Spirit-p1